1-4 of 4
Aradhana Tiwari
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Anthony N. Audino, MD, Matthew J. Barth, MD, Aradhana Tiwari, PhD, Dina Edani, MS, Janet Ayello, MS, MT(ASCP), Lauren Harrison, RN, MSN, Erin Morris, RN, BSN, Jessica C. Hochberg, MD, Stanton Goldman, MD, Christian Klein, PhD, Mitchell S Cairo, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3963.
https://doi.org/10.1182/blood-2019-128580
Published: 2019
Journal Articles

Polatuzumab Vedotin Alone or in Combination with Obinutuzumab Synergistically Enhances I n-Vitro Cytotoxicity and Cytokine Release Against CD20+/ CD79b+ Burkitt Lymphoma (BL) /Primary Mediastinal Large B Cell Lymphoma (PMBL)

Aradhana Tiwari, PhD, Dina Edani, MS, Janet Ayello, MS, MT(ASCP), Christian Klein, PhD, Dean Anthony Lee, MD PhD, Mitchell S. Cairo, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1540.
https://doi.org/10.1182/blood.V130.Suppl_1.1540.1540
Published: 2017
Journal Articles

Comparative Phosphoproteomics Study Between Obinutuzumab (GA101) Vs. Rituximab (RTX) Against RTX Sensitive/Resistant Burkitt Lymphoma (BL): Differentially Phosphorylated B Cell Receptor, Fc-Gamma Receptor, Phagocytosis and Natural Killer Cell-Mediated Cytotoxicity Signaling Pathway Proteins

Aradhana Tiwari, Delphine CM Rolland, PharmD, PhD, Mona Elmacken, MD, Janet Ayello, MS, Carmella van de Ven, MA, Venkatesha Basrur, PhD, Kevin Conlon, MS, Damine Fermin, PhD, Matthew J. Barth, MD, Christian Klein, PhD, Kojo Elenitoba-Johnson, Megan S Lim, MD PhD, Mitchell S. Cairo, MD
Journal: Blood
Blood (2015) 126 (23): 1550.
https://doi.org/10.1182/blood.V126.23.1550.1550
Published: 2015
Journal Articles

Deregulation of the PI3K/Akt Signal Transduction Pathway Is Associated with the Development of Chemotherapy Resistance and Can be Effectively Targeted to Improve Chemoresponsiveness in Burkitt Lymphoma Pre-Clinical Models

Sarah Frys, BSc, Natalie M Czuczman, BSc, Cory Mavis, BSc, MSc, Delphine C.M. Rolland, PharmD, PhD, Megan S Lim, MD PhD, Aradhana Tiwari, Mitchell S. Cairo, MD, Rodney R. Miles, MD PhD, Matthew J. Barth, MD
Journal: Blood
Blood (2014) 124 (21): 1769.
https://doi.org/10.1182/blood.V124.21.1769.1769
Published: 2014